Moreover, we found that silencing LINC00482 inhibited inflammation and angiogenesis in bladder cancer through the down-regulation of MMP-15 by targeting FOXA1, along with decreased levels of TNF-α, IL-1β, and IL-6 as well as the expression of VEGF and NF-κB. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.